Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Unknown 3

Sponsor Class

OTHER 160INDUSTRY 32NIH 14NETWORK 13OTHER_GOV 9UNKNOWN 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3CNS 1

Conditions

Breast Neoplasms 2Hormone Receptor Positive Advanced Breast Cancer 1Brain Neoplasms 1

Interventions

S 1 (combination) 12Capecitabine 11Paclitaxel 9Cisplatin 9apatinib 8Oxaliplatin 8pyrotinib 6nimotuzumab 6130-nm albumin-bound paclitaxel 6titanium silicide 5sintilimab 5camrelizumab 5anlotinib 5Etoposide 5Docetaxel 5Carboplatin 5Trastuzumab 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Bevacizumab 4Albumin-Bound Paclitaxel 4nedaplatin 3Vinorelbine 3Temozolomide 3Tegafur 3Taxes 3Radiosurgery 3Gemcitabine 3Fluorouracil 3Epirubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × UNKNOWN × Vinorelbine × Clear all
NCT03939871 2020-06-23

A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer

ChineseAMS

Phase 2 Unknown
30 enrolled
Breast

Hormone Receptor Positive Advanced Breast Cancer

NCT02768415 2019-06-19

Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer

ChineseAMS

Phase 2 Unknown
40 enrolled
Breast

Breast Neoplasms

NCT03933982 2019-05-29

Pyrotinib

ChineseAMS

Phase 2 Unknown
30 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡